At a scientific symposium in San Francisco last month, some of the country’s foremost experts on lupus shared their insights about the current state of lupus clinical trial design. Read more.
Insights from the 2014 American College of Rheumatology Reproductive Health Summit
Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.
Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.
Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Additional data from the CDC National Lupus Patient Registry project demonstrates that lupus is a widespread disease with a significant impact.